Liste des publications BETPSY
Biomarkers in autoimmune EncephaliTis and
Paraneoplastic neurological SYndromes
Articles Scientifiques
Salih LY et al. Direct Binding of FGFR3 Autoantibodies to Sensory Neurons Drives Hyperexcitability and Mechanical Pain Hypersensitivity. bioRxiv. doi: 10.1101/2025.06.01.657230.
Ciano-Petersen NL et al. Relapses in Anti-NMDAR Encephalitis: Clinical Characterization and Predictive Features. Neurol Neuroimmunol Neuroinflamm. 2025 Jul;12(4):e200421. doi: 10.1212/NXI.0000000000200421
Arzalluz-Luque J et al. Clinical course and long-term outcomes in autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy. J Neurol. 2025 May 26;272(6):421. doi: 10.1007/s00415-025-13159-0. (WP2)
Farina A et al. Application of the anti‑IgLON5 disease composite score to assess severity, clinical course, and mortality in a French cohort. Journal of neurology. 2025. 10.1007/s00415-025-13001-7 (WP2)
Peter E et al. Breast Cancer Specificities of Patients With Anti-Ri Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm. 2025. doi: 10.1212/NXI.0000000000200367 (WP4)
Ciano-Peterson et al. Paraneoplastic Neurologic Syndromes Associated With Merkel Cell Carcinoma. Neurol Neuroimmunol Neuroinflamm. 2024.doi:10.1212/NXI.0000000000200260 (WP2)
Peter E et al. Anti‑RGS8 paraneoplastic cerebellar ataxia is preferentially associated with a particular subtype of Hodgkin’s lymphoma. Journal of neurology. 2024.https://doi.org/10.1007/s00415-024-12618-4 (WP2)
Terroba-Navajas et al. Humoral signatures of Caspr2-antibody spectrum disorder track with clinical phenotypes and outcomes. Med. 2024.https://doi.org/10.1016/j.medj.2024.09.004 (WP2)
Dumez P et al. Specifc clinical and radiological characteristics of anti‑NMDA receptor autoimmune encephalitis following herpes encephalitis. Journal of neurology. 2024. https://doi.org/10.1007/s00415-024-12615-7 (WP2)
Farina A et al. Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study. Lancet. 2024. doi.org/10.1016/j.lanepe.2024.101011 (WP2)
Farina A et al. Opsoclonus-Ataxia Syndrome in a Patient With Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. Neurol Neuroimmunol Neuroinflamm. 2024. doi.org/10.1212/NXI.0000000000200287 (WP2)
Villéga F et al. Ketamine alleviates NMDA receptor hypofunction through synaptic trapping. Neuron. 2024. doi.org/10.1016/j.neuron.2024.06.028 (WP2)
Muñiz‑Castrillo S et al. HLA-DR3 ~ DQ2 associates with sensory neuropathy in paraneoplastic neurological syndromes with Hu antibodies. J Neurol. 2024. DOI: 10.1007/s00415-024-12534-7. (WP2)
Peris Sempere V et al. HLA and KIR genetic association and NK cells in anti-NMDAR encephalitis. Frontiers in immunology. 2024. doi.org/10.3389/fimmu.2024.1423149. (WP2)
Campetella et al. Corticospinal tract hyperintensity in patients with LGI1-antibody encephalitis and other central nervous system disorders with neuroglial antibodies. J Neuroimmunol. 2024. DOI: 10.1016/j.jneuroim.2024.578346. (WP2)
Lamblin et al. Nonparaneoplastic Autoimmune Encephalitis With GABABR Antibodies. Neurol Neuroimmunol Neuroinflamm. 2024. doi:10.1212/NXI.0000000000200229 (WP2)
Campetella et al. Predictors and Clinical Characteristics of Relapses in LGI1-Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2024 . doi: 10.1212/NXI.0000000000200228. (WP2)
Farina et al. Mononeuritis multiplex following immune checkpoint inhibitors in malignant pleural mesothelioma. Frontiers. 2024. https://doi.org/10.3389/fneur.2024.1338899 (WP2)
Villagran-Garcia et al. Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis. Brain Commun. 2023. 10.1093/braincomms/fcad247 (WP2)
Farina A. et al. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity, Brain Communications, Volume 5, Issue 3, 2023, fcad169, https://doi.org/10.1093/braincomms/fcad169 (WP2)
Bartley C. et al. Detection of High-Risk Paraneoplastic Antibodies against TRIM9 and TRIM67 Proteins. Ann Neurol. 2023. doi: 10.1002/ana.26776 (WP2)
Theuriet J. et al. Peripheral nervous system involvement accompanies central nervous system involvement in anti-glial fibrillary acidic protein (GFAP) antibody-related disease. J Neurol. 2023 ;270(11):5545-5560. doi: 10.1007/s00415-023-11908-7 (WP2)
Vogrig et al. Different Genetic Signatures of Small-Cell Lung Cancer Characterize Anti-GABABR and Anti-Hu Paraneoplastic Neurological Syndromese. Ann Neurol. 2023. https://doi.org/10.1002/ana.26784. (WP4)
Cluse F et al. Trigeminal Nerve Involvement in Bulbar-Onset Anti-IgLON5 Disease. Neurol Neuroimmunol Neuroinflamm. 2023 . doi: 10.1212/NXI.0000000000200153. (WP2)
Alentorn A et al. Spatial and Ecological Factors Modulate the Incidence of Anti-NMDAR Encephalitis—A Systematic Review. Neurol Neuroimmunol Biomedecine. 2023. https://doi.org/10.3390/biomedicines11061525. (WP2)
Schiff P et al. Anti-LGI1 Encephalitis With Co-occurring IgLON5 Antibodies: Clinical Features and Human Leukocyte Antigen Haplotypes. Neurol Neuroimmunol Neuroinflamm. 2023. doi: 10.1212/NXI.0000000000200126. (WP2)
Ciano-Petersen NL et al. Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2023. doi: 10.1212/NXI.0000000000200108. (WP2)
Vilaseca A et al. The expanding spectrum of antibody-associated cerebellar ataxia: report of two new cases of anti-AP3B2 ataxia. J Neurol. 2023. https://doi.org/10.1007/s00415-023-11732-z (WP2)
Flet-Berliac et al. Long-term outcome of paediatric anti-N-methyl-D-aspartate receptor encephalitis. Develomental medicine & child neurology 2023. https://doi.org/10.1111/dmcn.15429 (WP2)
Faure F et al. A Pilot Study to Develop Paraneoplastic Cerebellar Degeneration Mouse Model. The Cerebellum 2023. https://doi.org/10.1007/s12311-023-01524-6 (WP2)
Khatib L et al. Autoimmune Cerebellar Ataxia Associated withAnti‑Glutamate Receptor δ2 Antibodies: a Rare but Treatable Entity. The Cerebellum. 2023. https://doi.org/10.1007/s12311-023-01523-7 (WP2)
Farina A et al. Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors. Neurol Neuroimmunol Neuroinflamm. 2023. DOI: https://doi.org/10.1212/NXI.0000000000200058 (WP2)
Vabanesi M et al. SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniques. Journal of neurology. 2023. 10.1007/s00415-022-11523-y (WP2)
Benoit J et al. Early-Stage Contactin-Associated Protein-like 2 Limbic Encephalitis Clues for Diagnosis. Neurol Neuroimmunol Neuroinflamm. 2022. https://doi.org/10.1212/NXI.0000000000200041 (WP2)
Moritz C and al. Conformation-stabilizing ELISA and cell-based assays reveal patient subgroups targeting three different epitopes of AGO1 antibodies. Front. Immunol. 2022. https://doi.org/10.3389/fimmu.2022.972161 (WP2)
Villagran-Garcia M et al. Paraneoplastic neurological syndromes associated with renal or bladder cancer: case series and PRISMA-IPD systematic review. J Neurol. 2022. doi: 10.1007/s00415-022-11356-9 (WP2)
Peter E et al. Cerebellar Ataxia With Anti-DNER Antibodies: Outcomes and Immunologic Features. Neurol Neuroimmunol Neuroinflamm. 2022. doi: 10.1212/NXI.0000000000200018 (WP2)
Peter E et al. Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration. Neurol Neuroimmunol Neuroinflamm. 2022. 10.1212/NXI.0000000000200015 (WP4)
Peris Sempre V, Muñiz-Castrillo S, et al. Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2022. DOI: https://doi.org/10.1212/NXI.0000000000001140 (WP3)
Lardeux P et al. Core cerebrospinal fuid biomarker profile in anti‑LGI1 encephalitis. Journal of neurology. 2022. https://doi.org/10.1007/s00415-021-10642-2 (WP2)
Tholance Y et al. Anti-FGFR3 antibody epitopes are functional sites and correlate with the neuropathy pattern. Journal of neuroimmunology. 2021. https://doi.org/10.1007/s00415-021-10870-6 (WP2)
Vogrig A et al. Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis. Brain Communications. 2021. https://doi.org/10.1093/braincomms/fcab185 (WP2)
Do L and et al. Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases. Neurol Neuroimmunol Neuroinflamm. 2021. DOI: https://doi.org/10.1212/NXI.0000000000001032 (WP2)
Muñiz-Castrillo S, Hedou J, et al. Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis. Brain, 2021; awab153, https://doi.org/10.1093/brain/awab153 (WP3)
Muñiz‑Castrillo S, Haesebaert J et al. Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021. DOI: https://doi.org/10.1212/NXI.0000000000000974 (WP3)
Muñiz‑Castrillo S, Vogrig A et al. Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study. Journal of neurology. 2021. https://doi.org/10.1007/s00415-021-10424-w (WP3)
Moritz C, et al. CIDP Antibodies Target Junction Proteins and Identify Patient Subgroups. Neurol Neuroimmunol Neuroinflamm. 2021. doi.org/10.1212/NXI.0000000000000944 (WP2)
Vogrig A, et al. Cranial Nerve Disorders Associated with Immune Checkpoint Inhibitors. Neurology. 2020. doi.org/10.1212/WNL.0000000000011340 (WP2)
Moritz C et al. Proper definition of the set of autoantibody-targeted antigens relies on appropriate reference group selection. New biotechnology. 2020. doi.org/10.1016/j.nbt.2020.08.007 (WP2)
Hébert J, Riche B et al. Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurol Neuroimmunol Neuroinflamm. 2020; 7 (6). https://doi.org/10.1212/NXI.0000000000000883 (WP1-WP6)
Muñiz‑Castrillo S, Joubert B, et al. Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features. J Neurol Neurosurg Psychiatry. 2020; 0:1–9. doi.org/10.1136/jnnp-2020-323226 (WP3)
Muñiz‑Castrillo S, Vogrig A, Joubert B, and al. Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies. Cerebellum. 2020; 19 715-721. https://doi.org/10.1007/s12311-020-01159-x (WP2)
Vogrig A, Muñiz‑Castrillo S, Joubert B, et al. Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry. 2020; 91:772-778. doi: 10.1136/jnnp-2020-323212 (WP2)
Simard C, Vogrig A, Joubert B, et al. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol Neuroinflamm. 2020; 7:e699. DOI: https://doi.org/10.1212/NXI.0000000000000699 (WP2)
Déchelotte B, Muñiz‑Castrillo S, Joubert B, et al. Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurological syndromes. Neurol Neuroimmunol Neuroinflamm. 2020; 7(3):e701. https://doi.org/10.1212/NXI.0000000000000701 (WP2)
Muñiz‑Castrillo S, Ambati A, Dubois V, et al. Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies. J Neurol. 2020; 267:1906-1911. http://dx.doi.org/10.1007/s00415-020-09782-8 (WP3)
Vogrig. A, Gigli, G.L., Segatti, S. et al. Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol. 2020; 267: 26-35. http://dx.doi.org/10.1007/s00415-019-09544-1 (WP2)
Joubert, B., Belbezier, A., Haesebaert, J. et al. Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies. J Neurology. 2020. https://doi.org/10.1007/s00415-020-09807-2 (WP2)
Revues
Peter E et al. Mechanisms of immune tolerance breakdown in paraneoplastic neurological syndromes. Revue neurologique 2024. https://doi.org/10.1016/j.neurol.2024.08.002 (WP2)
Villagrán-García M et al. Dysautonomia in anti-Hu paraneoplastic neurological syndromes. J Neurol 2024. doi: 10.1007/s00415-024-12278-4. (WP2)
Vilaseca A et al. Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors. J Neurol. 2024. 10.1007/s00415-024-12252-0 (WP2)
Muñiz-Castrillo, S et al. Genetic predisposition to autoimmune encephalitis and paraneoplastic neurological syndromes. Current Opinion in Neurology. 2024 DOI: 10.1097/WCO.0000000000001263 (WP3)
Farina A et al. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol. 2024; 23: 81–94. doi.10.1016/S1474-4422(23)00369-1.(WP2)
Vogrig et al. Sudden unexpected death in epilepsy and ictal asystole in patients with autoimmune encephalitis: a systematic review. Neurological Sciences. 2024. https://doi.org/10.1007/s10072-023-07280-z (WP2)
Villagrán-García M et al. Autonomic nervous system involvement in autoimmune encephalitis and paraneoplastic neurological syndromes. Rev Neurol. 2023. doi: 10.1016/j.neurol.2023.12.001 (WP2)
Farina A et al. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management. Revue neurologique. 2023. https://doi.org/10.1016/j.neurol.2023.03.003 (WP2)
Campérat L et al. Autoimmune neuromyotonia. Curr Opin Neurol. 2022. 10.1097/WCO.0000000000001104. (WP2)
Antoine JC. Sensory neuronopathies, diagnostic criteria et causes. Curr Opin Neurol. 2022. Volume 4, Issue 4, 2022, fcac196, 10.1097/WCO.0000000000001105. (WP2)
Ciano-Petersen NL et al. Cytokine dynamics and targeted immunotherapies in autoimmune encephalitis. Brain communications. 2022. Volume 4, Issue 4, 2022, fcac196, https://doi.org/10.1093/braincomms/fcac196 (WP2)
Vaišvilas M, Ciano-Petersen NL, et al. Paraneoplastic encephalitis: clinically based approach on diagnosis and management. Postgrad Med J. 2022 -141766.
